YIELD10 BIOSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.261 USD | +2.35% |
|
-7.45% | +9.07% |
| Apr. 01 | Transcript : Yield10 Bioscience, Inc., Q4 2023 Earnings Call, Apr 01, 2024 | |
| Apr. 01 | Yield10 Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 2.25M | Sales 2025 * | 4M | Capitalization | 4.02M |
|---|---|---|---|---|---|
| Net income 2024 * | -11M | Net income 2025 * | -13M | EV / Sales 2024 * | 1.79 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1 x |
| P/E ratio 2024 * |
-0.35
x | P/E ratio 2025 * |
-0.31
x | Employees | 29 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.39% |
More Fundamentals
* Assessed data
More news
Latest transcript on Yield10 Bioscience, Inc.
More recommendations
More press releases
| 1 day | +2.35% | ||
| 1 week | -7.45% | ||
| Current month | -31.32% | ||
| 1 month | -30.40% | ||
| 3 months | +31.16% | ||
| 6 months | -20.91% | ||
| Current year | +9.07% |
1 week
0.25
0.29
1 month
0.220.45
Current year
0.190.72
1 year
0.183.29
3 years
0.1810.89
5 years
0.1858.80
10 years
0.183 624.00
| Managers | Title | Age | Since |
|---|---|---|---|
Oliver Peoples
FOU | Founder | 66 | 92-05-31 |
Charles Haaser
DFI | Director of Finance/CFO | 68 | 07-12-31 |
Kristi D. Snell
CTO | Chief Tech/Sci/R&D Officer | 56 | 96-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 06-09-30 | |
Richard Hamilton
BRD | Director/Board Member | 61 | 17-03-01 |
Oliver Peoples
FOU | Founder | 66 | 92-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 0.261 | +2.35% | 378,266 |
| 24-04-19 | 0.255 | -6.49% | 296,103 |
| 24-04-18 | 0.2727 | -2.08% | 353,277 |
| 24-04-17 | 0.2785 | -2.28% | 238,100 |
| 24-04-16 | 0.285 | +1.06% | 201,660 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotes
Yield10 Bioscience, Inc. is an agricultural bioscience company. The Company is using its differentiated trait gene discovery platform, the TraitFactory, to develop improved Camelina varieties for the production of seed products, and to discover high value genetic traits for the agriculture and food industries. The seed products include Camelina oil for use as a low carbon biofuel feedstock, Omega-3 oils for nutrition and PHA Bioplastics for biodegradable zero-waste packaging solutions. It is developing the oilseed Camelina sativa (Camelina) as a platform crop for large scale production of low carbon sustainable seed products to address petroleum replacement markets, food and nutrition markets, and animal feed markets. It is engaged in the development of elite Camelina germplasm exhibiting herbicide tolerance, disease resistance and other traits. The Company's development pipeline falls into three categories: input traits, performance traits and new seed product traits.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.261
USD
Average target price
0.5
USD
Spread / Average Target
+91.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.07% | 4.02M | |
| -0.02% | 42.11B | |
| +48.54% | 40.08B | |
| +5.04% | 40B | |
| -11.32% | 26.87B | |
| +5.25% | 24.58B | |
| -23.83% | 18.44B | |
| -1.62% | 11.94B | |
| +22.75% | 11.66B | |
| +6.44% | 11.01B |
- Stock Market
- Equities
- YTEN Stock
